Skip to content
DataLookout
Menu

NCT07697443

Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 31 words
    • Enrollment target: 306 to 300
    • Start date changed from estimate of Aug 2026 to Sep 12, 2026
    • Secondary endpoints: details revised at 7 of 12 entries
    • Site details revised at 6 of 6 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Dose Limiting Toxicity (DLT)
Timeframe: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
Maximum Tolerated Dose (MTD)
Timeframe: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
Recommended Phase II Dose (RP2D)
Timeframe: Observation is expected to continue through Cycle 6 Day 28 throughout the study, around 6 months.
Adverse Events (AEs)
Timeframe: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
Serious Adverse Events (SAEs)
Timeframe: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
Abnormal Incidence of Laboratory Test Indicators
Timeframe: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
Objective Response Rate (ORR)
Timeframe: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
Maximum Applicable Dose (MAD)
Timeframe: From the first dose of TQB3126 through completion of the Phase I dose-escalation assessment.

Secondary (12)

Peak Concentration (Cmax)
Time to Reach Maximum Plasma Concentration (Tmax)
Elimination Half-life (t1/2)
Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t)
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞)
Show 7 moreShow less
Apparent Clearance (CL/F)
Apparent Volume of Distribution (Vz/F)
Clinical Benefit Rate (CBR)
Disease Control Rate (DCR)
Duration of Response (DOR)
Progression-Free Survival (PFS)
Time to Response (TTR)

Arms and interventions

TQB3126Experimental

TQB3126 is to be administered orally in accordance with the protocol. Dose modifications and adjustments to the dosing frequency shall be made only with the unanimous consent of the SRC.

Drugs: TQB3126

Sites

6 sites in 1 country